← Back to patent-cliff list
厄贝沙坦
Tier C — Watch / tradeIrbesartan
赛诺菲
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：AT1
Brand：安博维、Karvea、Irbetan、Aprovel/Avapro、Aprovel/Karvea/Avapro、Avapro、Aprovel
Indications (approved)：食道疾病、高血压、糖尿病肾病
Regional status
US
批准上市
1997-09-30
EU
批准上市
1997-08-26
China
批准上市
2013-03-19
Japan
批准上市
2008-04-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Irbesartan?
Approved indications include: 食道疾病, 高血压, 糖尿病肾病.
When does the Irbesartan patent expire?
No public expiry year is available for Irbesartan yet; this page updates once verified.
How do I get a quote for Irbesartan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25